| scholarly article | Q13442814 |
| P2093 | author name string | Ling Zhang | |
| Wenhua Liu | |||
| Yanping Ma | |||
| Gu Jia | |||
| P2860 | cites work | The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. | Q40272775 |
| Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. | Q40498632 | ||
| The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. | Q40514693 | ||
| Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma | Q40520464 | ||
| Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors | Q40550020 | ||
| Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B | Q40623032 | ||
| Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells | Q42156460 | ||
| Molecular sequelae of histone deacetylase inhibition in human malignant B cells | Q44280918 | ||
| Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. | Q44564135 | ||
| Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells | Q46466046 | ||
| HDAC1 regulates fear extinction in mice. | Q47913817 | ||
| A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer | Q48199426 | ||
| Histone Deacetylase Inhibitors | Q55952250 | ||
| Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway | Q58862256 | ||
| Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells | Q24316070 | ||
| Chromatin modifications and their function | Q27861067 | ||
| Cell death: critical control points | Q28240722 | ||
| Clinical development of histone deacetylase inhibitors as anticancer agents | Q28244438 | ||
| The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain | Q28512719 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients | Q33429255 | ||
| Molecular sequelae of proteasome inhibition in human multiple myeloma cells | Q34393832 | ||
| Caspase-independent cell death | Q34433759 | ||
| HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo | Q34534191 | ||
| Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. | Q34562595 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 | ||
| The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells | Q35870933 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| HDAC inhibitors in kidney development and disease | Q37115414 | ||
| Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. | Q37217007 | ||
| Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. | Q37362054 | ||
| Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET/CT) Findings in an Unusual Case of Multiple Myeloma Presenting with a Large Extra-Axial Intracranial Mass | Q37523926 | ||
| A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance | Q37612692 | ||
| PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration | Q37822920 | ||
| Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors. | Q38388852 | ||
| Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma | Q38716460 | ||
| Panobinostat for the management of multiple myeloma | Q38806260 | ||
| Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Q39040044 | ||
| The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. | Q39040551 | ||
| Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation | Q39075781 | ||
| The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. | Q39121802 | ||
| P304 | page(s) | 5150-5157 | |
| P577 | publication date | 2017-10-29 | |
| P1433 | published in | Medical Science Monitor | Q15756323 |
| P1476 | title | Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms | |
| P478 | volume | 23 |
| Q58749971 | The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in Multiple Myeloma and its Prognostic Significance | cites work | P2860 |
Search more.